9 / 26
Page 34
Notes:
conferenceseries
.com
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
Pusceddu Claudio, Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-008
Percutaneous cryoablation in the treatment of metastatic breast cancer
Pusceddu Claudio
AOB Cagliari , Italy
M
etastatic breast cancer is considered an incurable disease, and the main treatment goal is palliation, with the aim of
maintaining or improving the quality of life and possibly improving survival. Palliative treatment options currently
available to these patients include external-beam radiotherapy, chemotherapy and combined modalities, endocrine therapies,
and biologic agents. Traditionally, the local treatment of stage IV breast cancer, through either surgery or radiotherapy, has been
reserved for palliation of advanced local disease to prevent local complications. Population and institutional data base reviews
suggest that a significant percentage of women (approximately 40%–60%) receive surgery for their primary breast tumor as a
component of therapy for stage IV disease. The biologic rationale for removing the primary breast tumor in cases of proven
disease dissemination is debatable, but several observational studies have exhibited a higher survival rate among patients with
stage IV breast cancer in whom the primary tumor is completely excised at the time of diagnosis. Ablative techniques, such as
radiofrequency ablation percutaneous cryoablation, interstitial laser ablation, and high-intensity focused ultrasound ablation,
are being explored in the hope to avoid the need for surgery. Among these local ablative therapies, percutaneous cryoablation
is a minimally invasive technique that has been proven to be a safe and effective technique for the treatment of local malignant
disease in various organs. The aim of this retrospective review of our hospital’s database was to assess the technical safety,
feasibility, and efficacy of percutaneous cryoablation to treat primary breast tumors in patients with metastatic breast cancer.
Biography
Pusceddu Claudio graduated in March 1986 from the University of Cagliari (Italy) and specialized at the same university in Diagnostic Radiology in 1996 and in
Medical Oncology in 2004. He has worked in an oncological hospital since 1992, and he has specialized in extra-vascular interventional radiology in the field of
Oncological Disease. Every year, he performs more than 300 procedures (radiofrequency thermal ablation, microwave ablation, cryoablation, percutaneous screws
fixation, osteoplasty with PMMA injection and combination of these procedures) in cancer patients.
clapusceddu@gmail.com